Clinical Trials Logo

Shock, Septic clinical trials

View clinical trials related to Shock, Septic.

Filter by:

NCT ID: NCT02961166 Completed - Septic Shock Clinical Trials

Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients

IVIG
Start date: January 2012
Phase:
Study type: Observational

57 patients with Adult Respiratory Distress Syndrome (ARDS) requiring Extracorporeal membrane oxygenation (ECMO) therapy were analyzed retrospectively. 28 patients had received immunglobulin M-enriched immunoglobulin therapy (IVIG); 29 patients did not receive IVIG therapy. These patients were analyzed regarding length of stay in intensive care unit (LOS ICU), length of stay (LOS) in hospital and regarding mortality.

NCT ID: NCT02960854 Completed - Severe Sepsis Clinical Trials

A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.

Start date: December 7, 2016
Phase: Phase 1
Study type: Interventional

A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.

NCT ID: NCT02934997 Completed - Sepsis Clinical Trials

The Role of Dysfunctional HDL in Sepsis

Start date: November 1, 2016
Phase:
Study type: Observational

To determine the role of dysfunctional high density lipoprotein (Dys-HDL) in predicting or mediating progression to chronic critical illness or morbid long-term outcomes in patients being treated for community-acquired or hospital-acquired sepsis.

NCT ID: NCT02918214 Completed - Septic Shock Clinical Trials

Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock

PRODIASYS2
Start date: January 2017
Phase:
Study type: Observational

Sepsis induces a reversible systolic and diastolic cardiac dysfunction. The presence of a left ventricular (LV) diastolic dysfunction during septic shock could favor harmful volume overload. Recently, a meta-analysis suggested a negative prognostic role of LV diastolic dysfunction in septic patients (Od Ratio: 1.82; 95%CI: 1.12 - 2.97; p = 0.02) but its external validity is hampered by the numerous limits and the heterogeneity of the studies. To date, a pathophysiological link between LV diastolic dysfunction associated with septic shock and the water balance (reflecting volume overload) remains to establish. In addition, small size studies reported an excess of mortality in patients with septic shock who were diagnosed with a high cardiac output. However, no large cohort has yet confirmed the negative prognostic role of a hyperkinetic hemodynamic profile at the initial phase of septic shock.

NCT ID: NCT02899897 Completed - Shock, Septic Clinical Trials

Place of Echocardiography in IV Fluid Therapy in Patients With Septic Shock and Left Ventricular Systolic Dysfunction

DYSPRED
Start date: January 2016
Phase:
Study type: Observational

IV fluid therapy remains an essential haemodynamic objective in the treatment strategy of septic shock. Left ventricular systolic dysfunction secondary to sepsis is observed in 40% and up to 65% of the population concerned. However, the capacity of the various indices to predict the response to IV fluid therapy in septic shock with left ventricular systolic dysfunction have not been clearly defined. Measurement of parameters reflecting filling pressures during transthoracic echocardiography (TTE) is one of the methods used to evaluate cardiac function and estimate the filling reserve, but with no strong evidence. Right heart catheterization with determination of cardiac output by pulmonary thermodilution can also be used to measure the various parameters commonly used to predict the response to IV fluid therapy. Very few data are available with no reliable and clinically relevant data in this population with septic shock and left ventricular systolic dysfunction (LVEF ≤ 40%) and the response to IV fluid therapy monitored by dynamic indices obtained by transpulmonary thermodilution and right heart catheterization. Consequently, the capacity of the various indices of preload dependence to predict the response to IV fluid therapy in septic shock with left ventricular systolic dysfunction remains difficult to define.

NCT ID: NCT02885168 Completed - Septic Shock Clinical Trials

Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C

PCA
Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose is to demonstrate that vasoreactivity of patients with septic shock evaluated with dose-response curve is diminished in septic shock and ameliorated by activated protein C (APC). This amelioration is correlated to decrease of inflammation, decrease of reactive oxygen species (ROS) markers and increase of circulating catecholamines.

NCT ID: NCT02884011 Completed - Septic Shock Clinical Trials

Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock

Start date: August 2016
Phase: N/A
Study type: Observational

Retrospective study to examine the effects of chronic antihypertensive medications on vasopressor dosing in septic shock

NCT ID: NCT02876341 Completed - Atrial Fibrillation Clinical Trials

Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

Start date: August 2016
Phase: N/A
Study type: Observational

Retrospective two-cohort study to determine the effect of chronic antihypertensive therapy on new onset atrial fibrillation and clinical outcomes in septic shock.

NCT ID: NCT02856191 Completed - Atrial Fibrillation Clinical Trials

Study on the Frequency of de Novo Atrial Fibrillation in Septic Shock in Medical Intensive Care

FACS
Start date: January 2011
Phase: N/A
Study type: Interventional

The aim of this pilot study is to determine, as exhaustively as possible thanks to the continuous and precise recording of heart rhythm, the frequency of de novo atrial fibrillation in septic shock, which is currently unknown, and to identify specific factors that could be associated with the condition. These will be investigated more precisely in a future study. This constitutes the first step in a reflection on the management of Cardiac Arrhythmia by Atrial fibrillation (ACFA) in septic shock in Medical Intensive Care, known as a major prognostic factor for morbimortality, but for which management is uncertain in the absence of reference data.

NCT ID: NCT02841241 Completed - Septic Shock Clinical Trials

Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia

ECASSS-R
Start date: April 2016
Phase: Phase 2
Study type: Interventional

This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion. The study will evaluate the adequacy and efficiency of study protocols for the anticipated, main ECASSS study, which will have a separate entry in clinicaltrials.gov.